Management of Highly Active Anti-retroviral Therapy-related Hyperlipidemia Among HIV-infected Patients in Taiwan

Tropical Medicine Center (TMC), Kaohsiung Medicine University Hospital (KMUH)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01697540

Enrollment

100

Registered

2012-10-02

Start date

2012-09-30

Completion date

2017-06-27

Last updated

2018-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Brief summary

1. Written informed consent must be obtained before any study specific procedures are undertaken. 2. The process of the experiment (brief describe) The patients must come back for follow during 4 to 12 weeks after starting the new therapy. The investigators will follow the patients' lipid profile and any side effects and stop the observation till 36 months after starting the new therapy. The serum level of HIV-VL, CD4, GOT, GPT, triglyceride, cholesterol, HDL-cholesterol, and LDL-cholesterol will be checked every 3 months. The patients' chart and all data will be delinked to protect the patients' right and privacy.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* HIV-infected patients who receive HAART therapy but have metabolic side effects. * Age over 20 years old

Exclusion criteria

* Abnormal liver function: GOT or GPT 5 times over normal upper limit

Countries

Taiwan

Outcome results